EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Effects of Naringenin in Preclinical Models of Breast Cancer

Emily C Irwin, Newman Siu Kwan Sze iD, Evangelia Tsiani iD

Biomolecules · 23.03.2026 · 16 (3) · 480

DOI: 10.3390/biom16030480 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Biomolecules, online erschienen am 23.03.2026. Verfasst von Emily C Irwin und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Health Sciences, Faculty of Applied Health Sciences, Brock University, St. Catharines, ON L2S 3A1, Canada. Hauptthemen laut MEDLINE: Flavanones, Breast Neoplasms, Antineoplastic Agents. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 67 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Breast cancer is the most commonly diagnosed cancer among women, with approximately one in eight women developing the disease during their lifetime. Despite advancements in current treatment options, breast cancer was responsible for an estimated 670,000 deaths worldwide in 2022. This highlights the urgent need for the development of novel therapeutic strategies. Historically, plant-derived compounds have played a significant role in cancer therapy, exemplified by widely used chemotherapeutic agents such as paclitaxel and docetaxel. In recent years, increasing attention has been directed toward novel plant-derived compounds as potential anti-cancer agents. Among these, Naringenin, a flavonoid predominantly found in citrus fruits, has shown promising antioxidant, anti-inflammatory, and anti-cancer properties. This review highlights recent studies investigating the effects of Naringenin and its derivatives on breast cancer. Evidence from both in vitro and in vivo animal models suggests that Naringenin may exert anti-tumor activity by inhibiting cell proliferation, promoting apoptosis, modulating key cell signaling pathways, and enhancing radio-sensitivity in breast cancer cells. Although preclinical evidence strongly supports the anticancer potential of Naringenin in breast cancer, comprehensive clinical studies are urgently needed to validate its efficacy and safety in humans.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

FlavanonesBreast NeoplasmsAntineoplastic AgentsHumansFemaleAnimalsApoptosisCell Proliferation

Stichwörter der Autor:innen

apoptosisbreast cancermetastasisnaringeninproliferation

Substanzen

FlavanonesnaringeninAntineoplastic Agents

Autor:innen und Institutionen

  • Department of Health Sciences, Faculty of Applied Health Sciences, Brock University, St. Catharines, ON L2S 3A1, Canada.
  • Centre for Bone and Muscle Health, Brock University, St. Catharines, ON L2S 3A1, Canada.

ORCID-Profile: Newman Siu Kwan Sze, Evangelia Tsiani

Zitieren

APA

Irwin, E. C., Sze, N. S. K., & Tsiani, E. (2026). Effects of Naringenin in Preclinical Models of Breast Cancer. Biomolecules, 16(3), 480. https://doi.org/10.3390/biom16030480

Vancouver

Irwin EC, Sze NSK, Tsiani E. Effects of Naringenin in Preclinical Models of Breast Cancer. Biomolecules. 2026;16(3):480. doi:10.3390/biom16030480

BibTeX
@article{Irwin2026,
  author = {Irwin, Emily C and Sze, Newman Siu Kwan and Tsiani, Evangelia},
  title = {Effects of Naringenin in Preclinical Models of Breast Cancer},
  journal = {Biomolecules},
  year = {2026},
  volume = {16},
  number = {3},
  pages = {480},
  doi = {10.3390/biom16030480}
}
Kostenlos starten →